Novo Nordisk's CEO, Mike Doustdar, faces mounting pressure from investors and analysts to articulate a clear strategy for the company's future growth, particularly beyond the success of its weight-loss drug, Wegovy. There are calls for Novo to establish medium-term targets and a roadmap that extends beyond its current reliance on semaglutide, the active ingredient in Wegovy. Some stakeholders are pushing for strategic acquisitions outside of the traditional obesity and diabetes sectors to mitigate impending patent cliffs.
Analysts are also suggesting that the recently approved oral Wegovy pill offers only a temporary solution to growth challenges. They advocate for prioritizing zenagamtide over CagriSema in Novo's pipeline. The company's Head of R&D, Martin Holst Lange, acknowledges the need for pipeline innovation and diversification. Novo is reportedly pursuing over 200 meetings this year to identify new drug candidates and platforms.
Novo's pipeline includes next-generation obesity treatments like CagriSema, a combination of semaglutide and cagrilintide, though initial analyst reactions to its weight loss efficacy have been lukewarm. The company is also developing triple-acting agonists, including one that combines GLP-1, GIP, and glucagon (acquired through a $2 billion deal with United Laboratories) and another that incorporates amylin biology, which Lange notes is a unique approach. Beyond obesity, Novo is exploring broader applications for its existing drugs and new candidates. This includes testing next-generation obesity drugs for conditions like sleep apnea and knee osteoarthritis.
Furthermore, Novo is engaged in high-risk, high-reward trials, such as the Zeus trial for ziltivekimab, which aims to reduce cardiovascular events in patients with specific conditions. Lange is also open to exploring new neurological applications for GLP-1 drugs, including addiction, following recent trials in Alzheimer's disease. This strategic shift aims to broaden the company's therapeutic reach and reduce its dependence on its current blockbuster, Wegovy, in the face of increasing competition from rivals like Eli Lilly.
